Leadership

Our talent team covers clinical medicine, bioinformatics and molecular biology, and has been in the precision medicine and high-throughput sequencing industries for many years.
At present, the company has more than 500 employees,
of which the doctoral proportion of the research and development system is over 21%, and the Master's degree is over 40%.

Do Bo
Founder & CEO
Du Bo graduated from the Department of Biology, Beijing University.

Genecast founder and CEO, is currently a young member of the Biomedical Technology Branch of the China Pharmaceutical Biotechnology Association.

Dubo is one of the first developers to enter the NGS field in China, and co-founded the first NGS reagent manufacturer in China, Nanjing Keweisi Biotechnology Co., Ltd.

Du Bo has been invited to attend conferences in the field of biomedical sciences and has been awarded many awards including the China Pharmaceutical Association's Technology Progress Award.

Du Bo graduated from the Department of Biology, Beijing University.

Zhang Henghui
Founder & CMO
Zhang Henghui graduated from the Peking University School of Medicine, China.

Henghui Zhang, M.D., PhD, Co-founder and Chief Medical Officer of Genecast (Beijing) Biotechnology Co. 

Henghui Zhang has been engaged in clinical and translational work for more than 10 years. This has endowed him with immense experience in clinical oncology and scientific research. He has participated in and lead a number of fund projects, including the National Natural Science Foundation of China, the Natural Science Funds of Beijing Municipality and the Doctoral Fund of Ministry of Education of China, among others. Simultaneously, he was a major participant in the national Eleventh Five-Year and Twelfth Five-Year Science and Technology Development Plans, has won four national invention patents, and has published more than 50 SCI papers. On top of this, he took the lead role of responsibility in the patent transfer of a new drug for a cancer vaccine therapy (0.12 billion RMB).

Prior to co-founding Genecast, Henghui Zhang worked at Peking University People’s Hospital and Peking University Hepatology Institute, and was engaged in clinical and translational work for more than 10 years. In roles such as project leader and co-leader, he was involved in preclinical development and research work for a number of therapeutic cancer vaccines and molecular diagnostics projects. 

Henghui Zhang graduated from Peking University with a master’s degree in medicine, and a doctorate in immunology from Capital Medical University.

Ma Guosheng
Founder & VP
Ma Guosheng graduated from the Medical College of Capital Medical University in 1988.

Guosheng Ma has more than 20 years of experience in the marketing and management of oncology drugs. He has obtained an in-depth understanding of the domestic pharmaceutical environment as well as its industry trends, and has unique insights into oncology drug marketing. 

In 2006, Guosheng Ma built a team of professionals to lead the launch of the anti-EGFR monoclonal antibody, cetuximab, in China and, in 2009, achieved sales of nearly 500 million yuan.

In 2010, Guosheng Ma joined Baitai Bio to lead up its marketing and sales. He successfully reversed its unfavorable market situation and grew sales of Nimotuzumab, China’s first independent anti-EGFR drug, to reach 500 million yuan, surpassing the market share of the original brand-name product by a multinational company.

Guosheng Ma studied medicine at Capital Medical University, graduating in 1988, and continued working there as an instructor until 1997.

Yang Tao
Vice General Manager
Yang Tao graduated from the Medical Department of Nanjing Medical College.

Tao Yang, deputy general manager of Genecast (Beijing) Biotechnology Co. 

Tao Yang has worked in the healthcare industry for more than a decade and has worked in marketing and management functions for well-known foreign and private pharmaceutical biotechnology companies, including Sino-Swiss joint venture Sino-Swed Pharmaceutical Co., Ltd., Sino-US joint venture Suzhou Lida Pharmaceutical Co., Ltd., Schering-Plough (China) Co., Ltd., Sino-American joint venture Shanghai Schering-Ploughs Pharmaceutical Co., Ltd., Beijing Zheng Qing Yuan Bio-Engineering Co., Ltd., and Nanjing Ai Qirui Molecular Biotechnology Co., Ltd.

Prior to this, Tao Yang worked for eight years at a clinical hospital as a physician, rising to the position of chief physician of internal medicine, and accumulating a wealth of experience in clinical medicine and medical management.

Tao Yang graduated in medicine from Nanjing Medical College.

He Ji
Chief information officer
He Wei graduated from Shanghai Jiaotong University majoring in information science and information management.

Ji He is the chief information officer of Genecast Biotechnology Co., Ltd. He has worked in many leading international enterprises, including OmniSeq, BioReference Laboratories, Leidos and Samuel Roberts Noble Foundation, where he lead in roles such as VP of bioinformatics, bioinformatics director, bioinformatics manager and director of scientific computing.

Ji He has an enormous amount of experience working internationally. He has more than a decade of experience in bioscience, and has gained outstanding achievements in genomics, biomedicine, informatics and computing. At OmniSeq, he developed the US’s first NGS diagnostic panel for cancer immunotherapy to be approved by NYS CLEP. He has published more than 40 articles in renowned international academic periodicals, including both Nature Genetics and Blood, and been in charge of seven research projects funded, with a total value of over 15 million dollars, by the United States Federal Government or state government. 

Bo Du
Founder & CEO

Bo Du is the Founder and CEO of Genecast Biotechnology Co. Ltd., he is also a member of the Biotech Diagnosis Branch of China Medicinal Biotech Association.


Bo Du studied biology at Peking University, and over the years since his graduation there, he has accumulated a wealth of experience in investment, pharmaceuticals, and second-generation sequencing. 

Henghui Zhang
Founder & Chief Medical Officer

Henghui Zhang, M.D., PhD, Founder and Chief Medical Officer of Genecast Biotechnology Co. Ltd.


Henghui Zhang has been engaged in clinical and translational work for more than 10 years. This has endowed him with immense experience in clinical oncology and scientific research. He has participated in and lead a number of fund projects, including the National Natural Science Foundation of China, the Natural Science Funds of Beijing Municipality and the Doctoral Fund of Ministry of Education of China, among others. Simultaneously, he was a major participant in the national Eleventh Five-Year and Twelfth Five-Year Science and Technology Development Plans, has won four national invention patents, and has published more than 50 SCI papers. On top of this, he took the lead role of responsibility in the patent transfer of a new drug for a cancer vaccine therapy (0.12 billion RMB).


Prior to co-founding Genecast, Henghui Zhang worked at Peking University People’s Hospital and Peking University Hepatology Institute, and was engaged in clinical and translational work for more than 10 years. In roles such as project leader and co-leader, he was involved in preclinical development and research work for a number of therapeutic cancer vaccines and molecular diagnostics projects. 


Henghui Zhang graduated from Peking University with a master’s degree in medicine, and a doctorate in immunology from Capital Medical University.

Guosheng Ma
Founder & Executive Vice President

Guosheng Ma is the Founder and executive vice president of Genecast  Biotechnology Co. Ltd.. Over many years he has worked for numerous well-known multinational pharmaceutical companies and private enterprises, including Bristol-Myers Squibb, Sanofi-Aventis, Merck Serono, and Baitai, serving as regional manager, regional director, national sales director, and deputy manager of marketing respectively.


Guosheng Ma has more than 20 years of experience in the marketing and management of oncology drugs. He has obtained an in-depth understanding of the domestic pharmaceutical environment as well as its industry trends, and has unique insights into oncology drug marketing. 


In 2006, Guosheng Ma built a team of professionals to lead the launch of the anti-EGFR monoclonal antibody, cetuximab, in China and, in 2009, achieved sales of nearly 500 million yuan.


In 2010, Guosheng Ma joined Baitai Bio to lead up its marketing and sales. He successfully reversed its unfavorable market situation and grew sales of Nimotuzumab, China’s first independent anti-EGFR drug, to reach 500 million yuan, surpassing the market share of the original brand-name product by a multinational company.


Guosheng Ma studied medicine at Capital Medical University, graduating in 1988, and continued working there as an instructor until 1997.

Tao Yang
Vice President & General Manager of Wuxi Site

Tao Yang, Vice President of  Genecast Biotechnology Co. Ltd., and General Manager of Wuxi Site. 

Tao Yang has worked in the healthcare industry for more than a decade and has worked in marketing and management functions for well-known foreign and private pharmaceutical biotechnology companies, including Sino-Swiss joint venture Sino-Swed Pharmaceutical Co., Ltd., Sino-US joint venture Suzhou Lida Pharmaceutical Co., Ltd., Schering-Plough (China) Co., Ltd., Sino-American joint venture Shanghai Schering-Ploughs Pharmaceutical Co., Ltd., Beijing Zheng Qing Yuan Bio-Engineering Co., Ltd., and Nanjing Ai Qirui Molecular Biotechnology Co., Ltd.

Prior to this, Tao Yang worked for eight years at a clinical hospital as a physician, rising to the position of chief physician of internal medicine, and accumulating a wealth of experience in clinical medicine and medical management.

Tao Yang graduated in medicine from Nanjing Medical College.

Ji He
Chief Information Officer

Ji He is the chief information officer of Genecast Biotechnology Co., Ltd., he has worked in many leading international enterprises, including OmniSeq, BioReference Laboratories, Leidos and Samuel Roberts Noble Foundation, where he lead in roles such as VP of bioinformatics, bioinformatics director, bioinformatics manager and director of scientific computing.


Ji He has an enormous amount of experience working internationally. He has more than a decade of experience in bioscience, and has gained outstanding achievements in genomics, biomedicine, informatics and computing. At OmniSeq, he developed the US’s first NGS diagnostic panel for cancer immunotherapy to be approved by NYS CLEP. He has published more than 40 articles in renowned international academic periodicals, including both Nature Genetics and Blood, and been in charge of seven research projects funded, with a total value of over 15 million dollars, by the United States Federal Government or state government. 


Ji He has extensive experience in research and management in both biomedicine and informatics, and has achieved impressive results. Just some of these include:


  1. leading a bioinformatics study of CLIA- and CLEP-certified laboratories, infrastructure, software engineering and production IT support, which focused on NGS tumor molecular tests;

  2. unifying and optimizing multiple pilot computing infrastructure systems; 

  3. leading the end-to-end development of bioinformatics channels of new molecular diagnosis tests in the field of genetics and oncology; 

  4. adopting a 24/7 workflow process for CLIA- and CAP-certified laboratories; and

  5. assisting in the transformation and development of computing and information settings (including hardware, software and personnel allocation) from SNP array platforms to the next-generation sequencing platforms.


Ji He earned a master’s degree in information science and information management from Shanghai Jiaotong University, and a PhD in computer science from the National University of Singapore. 

Weizhi Chen
Chief Scientific Officer

Weizhi Chen is the chief scientific officer of Genecast Biotechnology Co., Ltd., she has worked in several well-known enterprises at home and abroad, including Simcere Diagnostics (Jiangsu), GENEWIZ and SinoGenoMax, holding positions such as VP of R&D, director of R&D and operations and chief technical officer.


Weizhi Chen has been engaged in pharmaceutical research and development for many years and has an impressive background in medicine and molecular biology research. During her more than 20 years of work in biotechnology R&D in both China and the US, she has focused on medical R&D, company management, project operations and talent cultivation.


While at Simcere Diagnostics Weizhi Chen was in charge of the planning and execution of research and development strategies for clinical diagnostics and companion diagnostics product lines. She advanced technology platforms and quality management systems and guided development activities. She also lead teams in the development of precision medical products and services in clinical fields such as oncology, cardiovascular disease, neurology, autoimmunity, and infectious diseases.


Weizhi Chen is highly knowledgeable in all aspects of genomics and specializes in NGS research and clinical applications. At GENEWIZ she lead the GENEWIZ China R&D teams to advance NGS-based applications in the field of genomics. She was also in charge of operations and business development of molecular genetics and NGS product lines, and lead the development and commercialization of the company’s proprietary genomics-based antibody platform.


In addition to the above, Weizhi Chen was in charge of company's reagent development. She established comprehensive experimental facilities for drug R&D, including protein expression and purification, high throughput screening, and extraction and purification of natural products and cell cultures; and provided technical guidance for drug R&D. She has made many great academic achievement, including, but not limited to, publishing a number of articles in esteemed international academic periodicals, such as the European Journal of Neuroscience, the Journal of Biological Chemistry, and the Journal of Neuroscience.


Weizhi Chen earned her Doctor of Medicine degree at Peking Union Medical College, completed postdoctoral research at Harvard Medical School, and worked as an instructor at the Children’s Hospital of Boston, Harvard Medical School.

Jerry Wang
Vice President, Corporate Development

Dr. Jerry Wang, Vice President, Corporate Development at Genecast Biotechnology Co., Ltd, is responsible for the company’s business development and international collaboration. Prior to joining Genecast, he was head of market development at Illumina Greater China. This latter role followed Dr. Wang time at the Illumina headquarters in San Diego, California, where he accumulated more than seven years of BD experience overseeing new technology licensing, M&A and collaborations.  


He is well versed in sequencing industry dynamics and deeply involved in the development and marketing of various major sequencing platforms and applications, including the HiSeq-X instrument ($1000 genome), single-cell sequencing, and liquid biopsy technology development.  


Dr. Wang has also worked for Baxter BioScience, where he was responsible for licensing, and M&A in the areas of large molecule drug development, bio-surgery and regenerative medicine.  


He graduated from the University of Science and Technology of China. He also holds a PhD from Washington University in St. Louis and an MBA from the University of Chicago.